Gene therapy trial aims to fix protein deficiency at its source
Disease control
Not yet recruiting
This early-stage study is testing a new gene therapy called TSRA-196 for adults with severe Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can damage the lungs and liver. The main goals are to find a safe dose and see if the treatment can raise the body's levels …
Phase: PHASE1, PHASE2 • Sponsor: Tessera Therapeutics, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC